Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella’s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella’s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Copyright West LLC. Minimum 15 minutes delayed.
Presentation and webcast to take place at 11:30 a.m. ET on January 16 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2020-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex
Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks Interim data support candidates’ potential to become foundational NASH therapies Top-line data from full study expected in mid-2020
Preclinical mechanistic data for constituents of AXA4010 demonstrate multifactorial potential of endogenous metabolic modulators (EMMs) on red blood cell, immune and vascular health CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 7, 2019-- Axcella Health Inc.